NFKB1 and acute respiratory distress syndrome: As mentioned earlier, treatment with MSCs has the potential to reduce cytokine production associated with COVID-19-induced acute respiratory distress syndrome by targeting the molecular cascade of the NF-κB/NLRP3 pathway [35,36].